Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series

Gynecologic Oncology Reports
Koji MatsuoLynda D Roman

Abstract

Tumors deficient in DNA mismatch repair are known to display increased susceptibility to immune checkpoint inhibitors due to accumulation of DNA damage and increased neoantigen load. This suggests that deficiency in the BRCA-related DNA repair mechanism may also be a surrogate marker for immunotherapy response. The aim of this study was to examine the efficacy of the immune checkpoint inhibitor, nivolumab, in women with BRCA gene mutations and recurrent müllerian cancer. This retrospective case series followed six BRCA carriers who received nivolumab monotherapy (3.0 mg/kg, intravenous, day 1 and 15, every 4 weeks) as salvage therapy for recurrent epithelial ovarian (n = 5) and fallopian tubal (n = 1) cancers. Toxicity, treatment response, and survival were examined. Median age was 57 (range 51-64). BRCA1 and 2 mutations were equally distributed. All had high-grade serous histology, and all but one had advanced-stage disease at initial diagnosis. The majority had platinum-resistant disease (n = 4). All received salvage therapy prior to nivolumab therapy (median 3 lines), including PARP inhibitors (n = 3). The median number of nivolumab treatment cycles was 9, including 2 women receiving 18 cycles. Three women developed nivoluma...Continue Reading

Citations

Sep 25, 2018·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Tatyana V GorodnovaEvgeny N Imyanitov
Jul 20, 2019·Journal of Telemedicine and Telecare·Xiaoshi Yang, Carrie L Kovarik
Feb 23, 2019·International Journal of Molecular Sciences·Marco GreppiEmanuela Marcenaro
Nov 5, 2020·Antioxidants & Redox Signaling·Congying PuMin Huang
Aug 10, 2021·World Journal of Clinical Oncology·Evgeny Imyanitov, Anna Sokolenko
Aug 30, 2021·Hereditary Cancer in Clinical Practice·Evgeny N Imyanitov
Sep 9, 2021·Immunotherapy·Pauline RochefortChristelle de la Fouchardiere

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.